Log in
NASDAQ:MNTA

Momenta Pharmaceuticals Competitors

$52.48
0.00 (0.00 %)
(As of 10/2/2020)
Add
Compare
Today's Range
$52.48
Now: $52.48
$52.48
50-Day Range
$52.08
MA: $52.38
$52.49
52-Week Range
$12.21
Now: $52.48
$52.53
VolumeN/A
Average Volume1.94 million shs
Market Capitalization$6.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Competitors

Momenta Pharmaceuticals (NASDAQ:MNTA) Vs. AMGN, GILD, REGN, VRTX, BIIB, and SGEN

Should you be buying MNTA stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Momenta Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

Amgen has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Valuation & Earnings

This table compares Amgen and Momenta Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.64$7.84 billion$14.8215.17
Momenta Pharmaceuticals$23.87 million261.69$-290,050,000.00($3.03)-17.32

Amgen has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

75.2% of Amgen shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Amgen and Momenta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen30.04%91.98%15.24%
Momenta Pharmaceuticals-757.61%-61.44%-45.28%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Amgen and Momenta Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Momenta Pharmaceuticals07402.36

Amgen currently has a consensus target price of $255.48, indicating a potential upside of 13.60%. Momenta Pharmaceuticals has a consensus target price of $48.4444, indicating a potential downside of 7.69%. Given Amgen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Amgen is more favorable than Momenta Pharmaceuticals.

Summary

Amgen beats Momenta Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Volatility & Risk

Gilead Sciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Valuation & Earnings

This table compares Gilead Sciences and Momenta Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.77
Momenta Pharmaceuticals$23.87 million261.69$-290,050,000.00($3.03)-17.32

Gilead Sciences has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Momenta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences-1.16%33.59%11.89%
Momenta Pharmaceuticals-757.61%-61.44%-45.28%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Gilead Sciences and Momenta Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
Momenta Pharmaceuticals07402.36

Gilead Sciences currently has a consensus target price of $78.6538, indicating a potential upside of 31.18%. Momenta Pharmaceuticals has a consensus target price of $48.4444, indicating a potential downside of 7.69%. Given Gilead Sciences' higher possible upside, equities research analysts clearly believe Gilead Sciences is more favorable than Momenta Pharmaceuticals.

Summary

Gilead Sciences beats Momenta Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares Regeneron Pharmaceuticals and Momenta Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals37.30%26.71%19.39%
Momenta Pharmaceuticals-757.61%-61.44%-45.28%

Institutional and Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Regeneron Pharmaceuticals and Momenta Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals091412.67
Momenta Pharmaceuticals07402.36

Regeneron Pharmaceuticals currently has a consensus target price of $622.1250, indicating a potential upside of 6.21%. Momenta Pharmaceuticals has a consensus target price of $48.4444, indicating a potential downside of 7.69%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Regeneron Pharmaceuticals is more favorable than Momenta Pharmaceuticals.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Momenta Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.93$2.12 billion$21.4727.28
Momenta Pharmaceuticals$23.87 million261.69$-290,050,000.00($3.03)-17.32

Regeneron Pharmaceuticals has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Momenta Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Momenta Pharmaceuticals (NASDAQ:MNTA) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares Momenta Pharmaceuticals and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Momenta Pharmaceuticals-757.61%-61.44%-45.28%
Vertex Pharmaceuticals38.51%28.55%20.68%

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Momenta Pharmaceuticals and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Momenta Pharmaceuticals07402.36
Vertex Pharmaceuticals082012.76

Momenta Pharmaceuticals currently has a consensus target price of $48.4444, indicating a potential downside of 7.69%. Vertex Pharmaceuticals has a consensus target price of $294.00, indicating a potential upside of 41.93%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Momenta Pharmaceuticals.

Valuation and Earnings

This table compares Momenta Pharmaceuticals and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Momenta Pharmaceuticals$23.87 million261.69$-290,050,000.00($3.03)-17.32
Vertex Pharmaceuticals$4.16 billion12.96$1.18 billion$4.2948.29

Vertex Pharmaceuticals has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Momenta Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Momenta Pharmaceuticals (NASDAQ:MNTA) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares Momenta Pharmaceuticals and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Momenta Pharmaceuticals-757.61%-61.44%-45.28%
Biogen35.63%51.00%23.54%

Institutional & Insider Ownership

83.7% of Biogen shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Momenta Pharmaceuticals and Biogen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Momenta Pharmaceuticals07402.36
Biogen4151002.21

Momenta Pharmaceuticals currently has a consensus target price of $48.4444, indicating a potential downside of 7.69%. Biogen has a consensus target price of $306.8462, indicating a potential upside of 19.51%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Momenta Pharmaceuticals.

Valuation and Earnings

This table compares Momenta Pharmaceuticals and Biogen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Momenta Pharmaceuticals$23.87 million261.69$-290,050,000.00($3.03)-17.32
Biogen$14.38 billion2.75$5.89 billion$33.577.65

Biogen has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Momenta Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Momenta Pharmaceuticals (NASDAQ:MNTA) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.

Profitability

This table compares Momenta Pharmaceuticals and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Momenta Pharmaceuticals-757.61%-61.44%-45.28%
Seagen-25.17%-18.32%-15.49%

Institutional & Insider Ownership

92.0% of Seagen shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Comparatively, 31.1% of Seagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Momenta Pharmaceuticals and Seagen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Momenta Pharmaceuticals07402.36
Seagen161112.63

Momenta Pharmaceuticals currently has a consensus target price of $48.4444, indicating a potential downside of 7.69%. Seagen has a consensus target price of $172.3750, indicating a potential downside of 11.98%. Given Momenta Pharmaceuticals' higher probable upside, research analysts plainly believe Momenta Pharmaceuticals is more favorable than Seagen.

Valuation and Earnings

This table compares Momenta Pharmaceuticals and Seagen's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Momenta Pharmaceuticals$23.87 million261.69$-290,050,000.00($3.03)-17.32
Seagen$916.71 million37.17$-158,650,000.00($1.33)-147.24

Seagen has higher revenue and earnings than Momenta Pharmaceuticals. Seagen is trading at a lower price-to-earnings ratio than Momenta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Momenta Pharmaceuticals on 11 of the 15 factors compared between the two stocks.


Momenta Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$224.89flat$133.05 billion$23.36 billion18.37Upcoming Earnings
Dividend Announcement
Analyst Upgrade
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.7$59.96flat$75.17 billion$22.45 billion-249.82Upcoming Earnings
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
1.4$585.74flat$62.32 billion$7.86 billion22.68
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$207.15flat$53.96 billion$4.16 billion26.16Upcoming Earnings
Analyst Report
Heavy News Reporting
Biogen logo
BIIB
Biogen
1.7$256.76flat$40.78 billion$14.38 billion8.50Earnings Announcement
Analyst Revision
Seagen logo
SGEN
Seagen
1.3$195.83flat$34.07 billion$916.71 million-129.69Upcoming Earnings
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$120.76flat$26.65 billion$4.99 billion32.29Upcoming Earnings
Immunomedics logo
IMMU
Immunomedics
1.2$87.86flat$20.31 billion$290,000.00-50.79
Incyte logo
INCY
Incyte
1.6$90.44flat$19.78 billion$2.16 billion-99.38
Exact Sciences logo
EXAS
Exact Sciences
1.2$106.57flat$16.00 billion$876.29 million-100.54Upcoming Earnings
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$128.67flat$15.29 billion$219.75 million-17.00
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.7$76.88flat$14.06 billion$1.70 billion116.48
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.2$100.94flat$9.41 billion$788.10 million47.84Analyst Upgrade
Repligen logo
RGEN
Repligen
1.2$177.54flat$9.32 billion$270.24 million306.11
Exelixis logo
EXEL
Exelixis
2.1$21.90flat$6.77 billion$967.78 million24.61Analyst Report
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$47.01flat$6.57 billion$1.12 billion53.42
United Therapeutics logo
UTHR
United Therapeutics
1.5$123.57flat$5.49 billion$1.45 billion12.69Upcoming Earnings
Novavax logo
NVAX
Novavax
1.9$87.38flat$5.35 billion$18.66 million-31.77
Emergent Biosolutions logo
EBS
Emergent Biosolutions
1.1$95.29flat$5.04 billion$1.11 billion29.69
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.0$18.75flat$4.85 billion$182.24 million-16.45
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.2$85.50flat$4.69 billion$806.43 million-12.52
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.4$30.83flat$4.22 billion$195.99 million-118.58Upcoming Earnings
ChemoCentryx logo
CCXI
ChemoCentryx
1.5$53.20flat$4.05 billion$36.13 million-98.52Upcoming Earnings
Heavy News Reporting
Opko Health logo
OPK
Opko Health
2.4$4.31flat$2.89 billion$901.90 million-13.06Upcoming Earnings
Alkermes logo
ALKS
Alkermes
1.7$15.91flat$2.61 billion$1.17 billion-19.89Upcoming Earnings
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.6$128.96flat$1.99 billionN/A-14.81Analyst Upgrade
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$11.19flat$1.58 billion$102.43 million-13.48
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.5$9.57flat$1.53 billion$428.41 million15.69
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.8$84.94flat$1.37 billion$120.28 million-61.55Upcoming Earnings
Analyst Upgrade
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$14.28flat$1.07 billion$638.60 million-5.33Upcoming Earnings
Analyst Upgrade
Innoviva logo
INVA
Innoviva
0.9$9.82flat$995.67 million$261.02 million4.77
ImmunoGen logo
IMGN
ImmunoGen
1.6$5.47flat$954.75 million$82.27 million-12.72Analyst Report
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$28.84flat$951.17 million$252 million-2.78Upcoming Earnings
Analyst Downgrade
Codexis logo
CDXS
Codexis
1.5$13.98flat$852.31 million$68.46 million-58.25Upcoming Earnings
Agenus logo
AGEN
Agenus
1.5$3.65flat$722.76 million$150.05 million-3.20Upcoming Earnings
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
2.1$3.84flat$655.06 million$48.83 million-4.57
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.16flat$647.53 million$38.19 million35.55
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.6$15.40flat$638.54 million$3.57 million-5.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$10.43flat$570.01 million$227.19 million4.99Upcoming Earnings
Geron logo
GERN
Geron
2.0$1.83flat$568.16 million$460,000.00-4.95
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.40flat$495.50 million$109.33 million-2.79Analyst Report
Heavy News Reporting
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.24flat$492.17 million$143.01 million-0.86
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.4$2.27flat$486.12 million$150,000.00-3.24
MannKind logo
MNKD
MannKind
1.9$2.08flat$476.68 million$63.04 million-9.90
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.7$13.68flat$471.65 million$327.75 million-1.78High Trading Volume
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.23flat$460.75 million$22.27 million-3.55
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.5$3.93flat$430.38 million$35.22 million-2.30
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.5$2.44flat$412.19 million$59.29 million-17.43Upcoming Earnings
XOMA logo
XOMA
XOMA
2.1$23.48flat$258.70 million$18.37 million-21.15Upcoming Earnings
Analyst Upgrade
PDL BioPharma logo
PDLI
PDL BioPharma
2.0$2.23flat$254.18 million$54.76 million-1.68
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.